| Author(s) | Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
|
|---|
| Title | Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
|
|---|
| Source | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232
|
|---|
| Date | 2003 JUN
|
|---|
| Type | Journal : Article
|
|---|
| LCR: 9 NCR: 39 LCS: 3 GCS: 4
| | Comment |
|
|---|
| Address | Celgene Corp, Warren, NJ 07059 USA
Univ Calgary, Fac Med, Dept Physiol & Biophys, Calgary, AB T2N 1N4, Canada
|
|---|
| Reprint | Schafer, PH
Celgene Corp, 7 Powder Horn Dr, Warren, NJ 07059 USA
|
|---|
| Abstract | CC-4047 (Actimid) and CC-5013 (Revimid) belong to a class of thalidomide analogs collectively known as the immunomodulatory drugs (IMiDs), which are currently being assessed in the treatment of patients with multiple myeloma and other cancers. IMiDs potently enhance T cell and natural killer cell responses and inhibit tumor necrosis factor-alpha, interleukin ( IL)- 1beta, and IL-12 production from LPS-stimulated peripheral blood mononuclear cells. However, the molecular mechanism of action for these compounds is unknown. Herein, we report on the ability of the IMiDs to up-regulate production of IL-2 from activated human CD4(+) and CD8(+) peripheral blood T cells, production of IL-2 and IFN-gamma from T helper (Th) 1-type cells, and production of IL-5 and IL-10 from Th2-type cells. Elevation of IL-2 production from Jurkat T cells was observed as early as 6 h poststimulation and correlated with an increase in IL-2 promoter activity that was dependent upon the proximal but not the distal AP-1 binding site. The IMiDs enhanced AP-1-driven transcriptional activity 2-to 4-fold after 6 h of T cell stimulation, and their relative potencies for AP-1 activation correlated with their potencies for increased IL-2 production in Jurkat T cells and in CD4(+) or CD8(+) human peripheral blood T cells. The most potent of these IMiDs, CC-4047, had no effect on nuclear factor of activated T cells transcriptional activity, calcium signaling, or phosphorylation of extracellular signal-regulated kinase 1/2, c-Jun NH2-terminal kinase 1/2, p38 mitogen-activated protein kinase, or c-Jun/Jun D in Jurkat T cells. These data suggest that IMiDs increase T cell cytokine production by potentiating AP-1 transcriptional activity.
|
|---|
| CR |
BEERS SA, 1997, BIOORGAN MED CHEM, V5, P2203
CHEN HQ, 1997, J IMMUNOL, V159, P2274
CHIJIWA T, 1990, J BIOL CHEM, V265, P5267
CLIPSTONE NA, 1992, NATURE, V357, P695
CORADO J, 1990, CELL IMMUNOL, V126, P245
CORRAL LG, 1999, J IMMUNOL, V163, P380
DAVIES FE, 2001, BLOOD, V98, P210
DREDGE K, 2002, J IMMUNOL, V168, P4914
DUMONT FJ, 1998, J IMMUNOL, V160, P2579
FOLETTA VC, 1998, J LEUKOCYTE BIOL, V63, P139
GEPPERT TD, 1987, J IMMUNOL, V138, P1660
GOLLNICK SO, 2001, PHOTOCHEM PHOTOBIOL, V73, P170
HALL SR, 2001, IMMUNOLOGY, V104, P50
HASLETT PAJ, 1998, J EXP MED, V187, P1885
HIDESHIMA T, 2000, BLOOD, V96, P2943
HUDSON KR, 1993, J EXP MED, V177, P175
HUGHES CCW, 1996, J BIOL CHEM, V271, P5369
IACOBELLI M, 1999, J IMMUNOL, V162, P3308
JAIN J, 1992, J IMMUNOL, V148, P1240
JIMENEZ JL, 2001, J PHARMACOL EXP THER, V299, P753
KEIFER JA, 2001, J BIOL CHEM, V276, P22382
KELSO A, 1991, IMMUNOL REV, V123, P85
KHOSHNAN A, 2000, J IMMUNOL, V165, P6933
LIU J, 1991, CELL, V66, P807
LUXEMBOURG AT, 1998, J IMMUNOL, V161, P5226
MAJUMDAR S, 2002, J IMMUNOL, V168, P2644
MARRIOTT JB, 2002, CLIN EXP IMMUNOL, V130, P75
MARRIOTT JB, 2001, EXPERT OPIN BIOL TH, V1, P675
MORI A, 1999, J ALLERGY CLIN I S 2, V103, PS429
MULLER GW, 1999, BIOORG MED CHEM LETT, V9, P1625
OSWALD IP, 1994, J IMMUNOL, V153, P1707
PALMER EM, 1997, J IMMUNOL, V158, P2654
RICHARDSON PG, 2002, BLOOD, V100, P3063
SAEMANN MD, 2000, TRANSPLANTATION, V70, P1215
SCHAFER PH, 1999, J IMMUNOL, V162, P659
SCHAFER PH, 1999, J IMMUNOL, V162, P7110
SOLOMOU EE, 2001, J IMMUNOL, V166, P5665
SWEETSER MT, 1998, J BIOL CHEM, V273, P34775
YAN J, 1998, CHIN MED J, V111, P269
|
|---|
|
|